Cambridge UK, January 2013 - Antitope Ltd., UK (“Antitope”) today announced a Research Agreement with NeuroPhage Pharmaceuticals, Inc., USA (“NeuroPhage”) for the generation of a therapeutic protein with reduced immunogenicity. Under the Agreement, Antitope will apply it’s Composite ProteinTM deimmunisation technology to a next generation treatment for neurodegenerative diseases.
“We are delighted to be working with such an innovative company as NeuroPhage,” said Dr Matthew Baker, Chief Executive Officer and co-founder of Antitope, adding “This partnership utilises Antitope’s expertise in engineering non-immunogenic proteins to complement NeuroPhage’s innovations in developing novel therapeutics based on clearance of pathological protein aggregates.”
About Antitope
Antitope Ltd. is a privately-held Cambridge UK-based biotechnology company specialising in immunogenicity testing and the engineering of therapeutic antibodies/proteins with reduced immunogenicity. Antitope’s proprietary EpiScreen™ technology enables preclinical analysis of the potential for immunogenicity of therapeutic antibodies and proteins. Antitope’s proprietary Composite Human Antibody™ and Composite Protein™ technologies result in the generation of proteins and humanised antibodies devoid of T cell epitopes. Antitope has established multiple commercial relationships with leading biotechnology and pharmaceutical companies worldwide.
For more information, please visit www.antitope.co.uk.or contact:
Antitope Ltd.
Dr Neil Butt, Business Development Director
Tel: +44 (0)1223 496190
Emai: info@antitope.co.uk
About NeuroPhage Parmaceuticals, Inc.
NeuroPhage is a biotechnology company focusing on a unique disease-modifying approach for treating protein aggregation diseases. NeuroPhage was founded in 2007 by a team based in Cambridge, MA, USA, along with Professor Beka Solomon, Chair for Biotechnology of Neurodegenerative Diseases at Tel Aviv University.
For more information, please visit www.neurophage.com or contact info@neurophage.com
